Global Engage

THE RESEARCH & TECHNOLOGY SERIES: IMMUNO-ONCOLOGY

– LONDON UK –

10-11 October 2019

London Heathrow Marriott Hotel

Diamond Sponsor

NEO GENOMICS

Platinum Sponsor

BECKMAN COULTER Life Sciences

STILLA

Gold Sponsors

Novogene

BIO-RAD

TWIST BIOSCIENCE

#randtseries

www.global-engage.com

www.global-engage.com/event/research-technology-series

WARM WELCOME

Global Engage

Immuno-oncology has already established itself as a vital weapon in the fight against cancer, and with a market value expected to reach $125 billion by 2024 it continues to revolutionize patient care.

The Research & Technology Series: Immuno-oncology is a multi-event forum exploring the latest scientific and technological advances in novel cancer targets, biomarker detection and large molecule therapeutics, with five co-located meetings in key areas of immuno-oncology drug and technology development: Liquid Biopsies, TMB & Neoantigens, Flow Cytometry, Novel Antibody Therapeutics and Adoptive Cell Transfer

With delegates having access to all 100 presentations across the five events, this series will bring together over 400 industry and academic leaders at the cutting edge of research to keep you abreast of the latest scientific, clinical and regulatory innovations and advances, and provide you with the opportunity to network with industry experts, researchers, investors and potential partners.

POSTER PRESENTATIONS

MAKING A POSTER PRESENTATION

Poster presentation sessions will take place in breaks and alongside the other breakout sessions of the conference. Your presentation will be displayed in a dedicated area, with the other accepted posters from industry and academic presenters. We also issue a poster eBook to all attendees with your full abstract in and can share your poster as a PDF after the meeting if you desire (optional). Whether looking for funding, employment opportunities or simply wanting to share your work with a like-minded and focused group, these are an excellent way to join the heart of this congress.

In order to present a poster at the congress you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). We charge an admin fee of £100 to industry delegates to present, that goes towards the shared cost of providing the poster presentation area and display boards, guides etc. This fee is waived for those representing academic institutions and not for profit organisations.

TMB & NEOANTIGEN CONGRESS

EXAMINING ADVANCEMENTS IN NOVEL TARGETS, PREDICTIVE BIOMARKERS AND PERSONALISED MEDICINE

DAY 1 THURSDAY 10TH OCTOBER 2019

08:00 - 08:50 Registration & Refreshments

08:50 - 09:00 Welcome Address and Morning Chair's Opening Remarks

TARGETING THE TMB

09:00 - 09:40

KEYNOTE ADDRESS:
RAJIV RAJA Director, Oncology Translational Medicine, AstraZeneca, USA
ctDNA-based biomarkers in immuno-oncology drug development: opportunities and challenges
Circulating tumor DNA (ctDNA) derived from plasma offer significant promise as a tool for assessing tumor burden and antitumor response. Changes in levels of ctDNA from baseline have been shown to correlate with response to some immunotherapies. Recent studies have also shown that ctDNA could be used to measure tumor mutation burden (TMB) which could be a potential predictive biomarker for response to immunotherapies. ctDNA results from immunotherapy studies will be discussed, and opportunities and challenges with ctDNA analysis will be discussed.

09:40 - 10:20

KEYNOTE ADDRESS:
CHRISTOPHE LE TOURNEAU Head, Department of Drug Development and Innovation (D3i), Institut Curie, France
Optimising patient benefit whilst reducing toxicity risk
Optimising patients benefit whilst reducing toxicity risk is the ultimate goal of precision medicine in oncology. While precision medicine has always been a reality in medicine with treatments adjusted based on the clinical condition of patients, the term "precision medicine" has arisen with the advent of molecularly targeted therapies that were developed based on biomarkers that were mostly DNA alterations. Precision medicine does not apply only for molecularly targeted therapies but also for immunotherapeutics especially immune checkpoint inhibitors, for which predictive biomarkers of efficacy have been identified at the genomic level.

10:20 - 10:50 **SENIOR REPRESENTATIVE**
Novogene

10:50 - 12:00 Morning Refreshments / Poster Presentations

12:00 - 12:30 **WILL SPOONER** Commercial Programme Delivery Lead, Genomics England, UK
Will whole genome sequencing of fresh frozen tumour material become the assay of choice for cancer molecular diagnostics?
At the start of the 100,000 Genomes Project it became clear that formalin fixed paraffin embedded tumour material was not suitable for whole genome sequencing. An alternative "WGS friendly" fresh frozen protocol (FF-WGS) was developed and implemented as a clinical pathway in the NHS. This protocol has been used to generate a dataset of linked genome-to-health data from 15,000 cancer cases. Analysis of the dataset suggests that our FF-WGS assay that has the potential to more reliably and accurately measure cancer markers such as TMB. This talk presents these data and considers the challenges of introducing FF-WGS-based tests into clinical trials and practice. Finally we speculate on the mining of large FF-WGS datasets to identify the next generation of cancer biomarkers.

12:30 - 13:00 **MARTIN ZOCHE** Director Molecular Tumor Profiling, University Hospital Zurich, Switzerland
TMB and MSI in clinical application using comprehensive tumor profiling
- Comprehensive molecular tumor profiling is standard at the University Hospital Zurich is as a diagnostic standard procedure for all tumor patients.
- Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) analysis are integrated in the molecular report and discussed.
- Patient cases will illustrate the advantages for the tumor patients

13:00 - 13:30 **SENIOR REPRESENTATIVE**
Oncoimmunity

13:30 - 14:30 **Lunch**

TARGETING NEOANTIGENS

14:30 - 15:00 **PAMELA CARROLL** Senior Vice President, Scientific Strategy, Genocea Biosciences, USA
ATLAS™ – A Critical Tool in Finding True Neoantigens
- ATLAS™ is a powerful tool that screens all candidate neoantigens for pre-existing patient-specific CD4 or CD8 responses in an HLA agnostic assessment.
- ATLAS also identifies inhibitory peptides that may suppress tumor immunity, accelerate tumor progression and mediate patient response to immune checkpoint blockade therapies.
- ATLAS-selected neoantigens are the basis of a vaccine, GEN-009, currently being evaluated in Phase 1/2a clinical trials. Also, ATLAS is being applied to a personalized non-engineered T cell therapy program that targets multiple neoantigens.

15:00 - 15:30 **ELISA SCARSELLI** CSO, Nouscom, Italy
Combined treatment with checkpoint blockade and Adenovirus vaccine targeting multiple neoantigens eradicates large tumors in mice
- Non-human Great Ape Adenoviruses (GAd) are potent vaccine vectors able to encode many neoantigens
- Vaccination synergizes with α-PD-1 in mice bearing large established tumours
- Combined treatment results in diversification of the intra-tumor T cell repertoire

16:00 - 16:15 **AGNETE FREDRIKSEN** President and CSO, Vaccibody, Norway
Considerations and experiences from taking a fully personalized targeted cancer neoantigen DNA vaccine into the clinic.
- What is the rationale to pursue development of individualized cancer vaccines and make it a viable product for the market?
- How does the vaccine format affect the immunogenicity profile of individual neoepitopes?
- Update from DIRECT-01, a clinical trial testing private cancer neoantigen based vaccines in patients with advanced cancer

16:15 - 16:30 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch: Sponsorship@globalengage.co.uk

16:30 - 17:20 Afternoon Refreshments / Poster Presentations

17:20 - 17:50 **SARAH MISSEL** Director, Translational Development, R&D Strategy and Communications, Immatics, Germany
Tailor-made immunotherapies: Integrating non-mutated and neoantigens into highly personalized immunotherapy approaches
- The role of neoantigens and non-mutated antigens in tumors with low mutational burden
- GAPVAC - Actively Personalized Vaccination in newly diagnosed glioblastoma patients - results of the clinical study GAPVAC-101
- Highly personalized Adoptive Cellular Therapy

17:50 - 18:20 **KAÏDRE BENDJAMA**
Project Leader, Personalized Cancer Vaccination, Transgene, France
Viral-based vaccine for cancer neoantigen vaccination
Viral vectors constitute a promising modality for cancer vaccines. Viral vectors were used successfully to generate cancer vaccines in a number of indications using Tumor associated antigen as targets to induce a specific T cell response. The presentation will provide an overview on how Transgene uses the MVA viral strain to meet specific challenges related neoantigen vaccination from sequencing to neoepitope selection to manufacturing and QC to deliver a clinical grade product and on how these vaccines will be translated into the clinic in indications of high medical needs.

18:20 **Closing Remarks** / End of Day 1

18:20 - 19:20 **Networking Drinks Reception**

DAY 2 FRIDAY 11TH OCTOBER 2019

08:15 - 08:55 Refreshments

08:55 - 09:00 Morning Chair's Opening Remarks

QUANTIFICATION OF TMB AND NEOANTIGEN LOAD

09:00 - 09:40

KEYNOTE ADDRESS:
GEORGE VASMATZIS Co-director of the Biomarker Discovery Program, Associate Professor, Department of Molecular Medicine, Mayo Clinic, USA (Reserved)

Chromoplexis and chromothripsis can increase neoantigen load

- We observed that inter- or intrachromosomal rearrangements are present in many cancers frequently in a pattern of chromoanagenesis such as chromoplexy or chromothripsis.
- Transcription of rearrangement-related junctions was predicted to result in many potential neoantigens, some of which were proven to bind patient-specific major histocompatibility complex molecules and to expand intratumoral T cell clones.
- Subsets of prostate, lung, and breast, cancers as well as some sarcomas are among those that could present neoantigens that derive from complex rearrangements

09:40 - 10:10

ANDREAS WEINHÄUSEL Thematic Coordinator, Molecular Diagnostics, AIT – Austrian Institute of Technology, Austria

PepPipe – an immunomics workflow elucidating antigenic peptide biomarker signatures for minimal invasive diagnostics

Autoantibody & antibody-profiles are biologically meaningful and suitable as early and minimal invasive markers using 10µl of plasma or serum. Since the immune system plays a major role in many diseases, sero-testing and immunomics analysis has a broad area of application and a high potential for diagnostics of autoimmune, cancerous, cardiologic, neurodegenerative and systemic diseases, as well as assisting biotech and pharma for selecting therapeutic targets or study off-target reactivities. PepPipe provides an entire workflow of optimised and QM qualified methods to define antigenic proteins and peptides for serological analysis. We have developed a broad variety of assays with different multiplexing capacities to provide the entire workflow "from screening to validation" and "from proteins to peptides" to define and analyse antigenic proteins and peptides supporting clinical and therapeutic developments, and improving robust minimal invasive diagnostics.

10:10 - 10:40 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

10:40 - 11:50 Morning Refreshments / Poster Presentations

11:50 - 12:20 **EUN-ANG RAIBER-MOREAU** Associate Principal Scientist, AstraZeneca, UK

The promise and challenge of TMB in the clinics for immunotherapy

Tumour mutational burden (TMB) is emerging as an important biomarker that hold promise to aid in the selection of patients for immunotherapy. TMB is defined as the total number of mutations per megabase within the coding area of the genome. TMB was initially assessed using whole exome sequencing but new studies have shown that targeted NGS panels can be used for TMB calling reducing down the costs and turn-around time. In this presentation, we will discuss the challenges of implementing TMB testing into routine clinical settings with a focus on the importance of TMB standardization and blood versus tissue TMB testing

12:20 - 12:50 **TEDD HUPP** Chair of Cancer Research, University of Edinburgh, UK

Developing proteogenomcis platforms in cancers of high unmet clinical need

Proteogenomics platforms are being developed that can reveal the expressed cancer genome as we evolve towards personalized therapies. Our network aims to (i) define comprehensively the biological sources of cancer neoantigens; (ii) evolve algorithmic strategies for mass-spectrometry based mutation identification; (iii) identify novel genes that regulate MHC Class I production in cancers; and (vi) apply this knowledge on the mutant peptidome to form therapeutic options in cancers of high unmet clinical need.

12:50 - 13:20 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

13:20 - 14:20 **Lunch**

14:20 - 14:50 **JENS KRINGELUM** Director, Genomic Immuno Oncology, Evaxion Biotech, Denmark

Using Artificial Intelligence to accelerate Immunotherapy

- What is AI and how can it be used to predict immune responses in patients
- The use of AI driven prediction tools for design of novel immunotherapies
- Opportunities and challenges in using AI technology to drive truly personalised treatments

14:50 - 15:20 **ASTRID VISSER** Business Development Manager, Sanquin, The Netherlands

Application of in vitro tools that improve selection of (neo) epitopes and characterize T cell responses

- Measured peptide-MHC binding / stability that improves (neo) epitope selection
- Multi-parameter FACS that efficiently detects and characterizes multiple pre-existing and induced epitope-specific T-cell responses
- Efficient peptide-MHC-exchange based assay that allows cross-reactivity and safety studies for peptide-MHC-antibodies and TCR mimics

15:20 - 15:50 **ALEX FRANZUSOFF** CEO, PACT Pharma

Personalized NeoTCR-T Cell Therapies for Solid Tumors

PACT Pharma is developing personalized tumor-mutation (neoantigen or neoepitope) targeted T cells tailored for each patient. Using (non-viral) precision genome engineering, a fresh collection of autologous patient T cells are re-programmed to produce 'native' autologous tumor mutation-targeted T cells (neoTCR-T cells) for administration as a 'living drug' back to the patient. In this talk, I will discuss PACT's development of neoTCR-T cell products exclusively for each patient, as well as the remarkable landscape of neoE-specific T cells (direct capture) in blood or TILs of patients, as well as the evolution of neoE-T cell responses in I-O trials. These developments represent a new frontier for programming fresh, autologous human T cells with 'new tricks' to personalize the treatment of patients with the spectrum of solid tumors.

15:50 - 16:20 **TIM FUGMANN**
Senior Scientist, Max Delbrück Center and Senior Scientific Advisor, Alithea Bio, Switzerland

Profiling of neo-antigens presented by cancer cells facilitate patient stratification and development of potent anti-tumor therapies

- Aberrantly expressed transcripts lead to presentation of neo antigens on cancer cells
- Aberrant expression is a common event leading to antigens shared between multiple tumors
- Such neo antigens can be targeted by adoptive T cell therapies

16:20 **Conference Close**

Track Switch
Listen to any talk - Attendees are encouraged to move between Congresses

LIQUID BIOPSIES CONGRESS

EXPLORING THE DIAGNOSTIC, PROGNOSTIC AND THERANOSITC APPLICATIONS OF LIQUID BIOPSIES

DAY 1 THURSDAY 10TH OCTOBER 2019

08:00 - 09:00 Registration & Refreshments

08:50 - 09:00 Welcome Address and Morning Chair's Opening Remarks: **Iwanka Kozarewa,** Senior Scientist – Translational Genomics, AstraZeneca, UK

OPPORTUNITIES AND CHALLENGES

09:00 - 09:40

KEYNOTE ADDRESS

MATT TRAU Professor of Chemistry, Deputy Director and Co-Founder of AIBN, University of Queensland, Australia

A universal biomarker for cancer: Are we there yet?

Epigenetic reprogramming in cancer genomes creates a distinct methylation landscape encompassing clustered methylation at regulatory regions separated by large intergenic tracks of hypomethylated regions. This methylation landscape that we referred to as Methylscape is displayed by most cancer types, thus may serve as a universal cancer biomarker. We examine the effect of levels and genomic distribution of methylcytosines on the physicochemical properties of DNA to detect the Methylscape biomarker. We find that DNA polymeric behaviour is strongly affected by differential patterning of methylcytosine, leading to fundamental differences in DNA solvation and DNA-gold affinity between cancerous and normal genomes. We exploit these Methylscape differences to develop simple, highly sensitive and selective electrochemical or colorimetric one-step assays for the detection of cancer. These assays are quick, i.e., analysis time ≤10 minutes, and require minimal sample preparation and small DNA input from either solid or liquid biopsies.

09:40 - 10:20

KEYNOTE ADDRESS

SIMON LUCAS Innovation Field Explorer, Merck KGaA

Enabling Liquid Biopsy in Cancer and Beyond

The early detection of life-threatening conditions as well as the selection of individualized treatment options for affected patients will have significant potential to disrupt our current public health sectors. Recently, alternatives to traditional tissue biopsy, such as liquid or breath biopsy, have emerged as attractive tools for the detection and management of various diseases and especially in the therapeutic area of oncology. While cancer detection with liquid biopsy is gaining acceptance, other indications often still lack a non-invasive diagnostic test, even though precision medicine is viewed as an important concept in indications outside oncology. This talk highlights the opportunities of liquid biopsy in cancer and beyond as well as our efforts at Merck to address challenges in the field with new enabling technologies.

10:20 - 10:50 **SENIOR REPRESENTATIVE**
Stilla

10:50 - 12:00 Morning Refreshments / Poster Presentations

DETECTING CIRCULATING BIOMARKERS

12:00 - 12:30 **ANDERS STAHLBERG** Associate Professor, University of Gothenburg, Sweden

Considerations when analyzing cell-free tumor DNA

- Analysis of circulating cell-free tumor DNA (ctDNA) in liquid biopsies offers new means for early cancer diagnostics, real-time monitoring of treatment efficiency and detection of relapse. Despite its potential use ctDNA remains challenging to detect and to quantify as it represents only a small fraction of all cell-free DNA.
- We have developed SiMSen-Seq, that allows allele frequencies < 0.1% to be detected. SiMSen-Seq is simple to perform, flexible in multiplexing and requires minimal DNA input.
- Here, we discuss important considerations for ctDNA analysis in plasma, including all experimental steps from sampling to data interpretation. Furthermore, the use of quality control assays enables the development of robust and standardized workflows that facilitate the implementation of ctDNA analysis into clinical routine.

12:30 - 13:00 **AN HENDRIX** Assistant Professor, University of Ghent, Belgium

Standardized analysis of extracellcular vesicles in liquid biopsies

The identification of extracellular vesicle (EV)-associated biomarkers is challenging owing to the complexity of liquid biopsies. We 1) performed quality control studies to identify the impact of (pre-) analytical variables on biomarker identification, 2) developed reference materials to ensure standardized EV measurements, and 3) created EV-TRACK to stimulate researchers to put experimental guidelines into practice. This combined expertise boosted the identification of bacterial EV in the systemic circulation of patients with intestinal barrier dysfunction.

13:00 - 13:30 **SENIOR REPRESENTATIVE**
BioRad

13:30 - 14:30 **Lunch**

14:30 - 15:00 **DOLORES CAHILL** Professor of Translational Science, University College Dublin, Ireland

Innovation in Research: From Protein Array to Companion Diagnostics to Profiling of Adverse Events

Overview of profiling the autoantibody repertoire on high content protein arrays and using this approach to identify biomarkers, and develop diagnostics and companion diagnostics.

15:00 - 15:30 **JEAN-YVES PIERGA** Institut Curie, Department of Medical Oncology and Circulating Tumor Biomarkers Laboratory, SiRIC, Université Paris Descartes, France

Clinical utility of CTC and ctDNA in metastatic and neo/adjuvant setting of breast cancer

Circulating tumor cells (CTCs) have been identified as potential blood-based biomarker capable of providing prognostic and predictive information in breast cancer. Their applications include early diagnosis, prognostic assessment, detection of minimal residual disease, early detection of cancer relapse and management of metastatic disease. The clinical validity of the CTC-based liquid biopsy has been already assessed by numerous studies. Pooled analysis of large clinical data set in adjuvant, neoadjuvant and metastatic setting are now available. Recent results of clinical trial could support their clinical utility. The potential applications for circulating tumour DNA (ctDNA) in early and metastatic setting include prognosis assessment before treatment initiation, early assessment of treatment efficacy and help to guide personalized therapies.

15:30 - 16:00 **IWANKA KOZAREWA**
Associate Principal Scientist, Translational Medicine, AstraZeneca, UK

16:00 - 16:30 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

16:30 - 17:20 Afternoon Refreshments / Poster Presentations

17:20 - 18:20 PANEL DISCUSSION:

Translating liquid biopsies into routine care

KATARZYNA WITKOWSKA
Commercial Partnerships Manager, Genomics England, UK

KAREN SPINK
Innovation Lead – Precision Medicine, Innovate UK

ALEXANDRE HARLÉ
Assistant Professor, Molecular Biologist, Institut de Cancérologie de Lorraine, France

IWANKA KOZAREWA
Senior Scientist, AstraZeneca, UK

BERNHARD POLZER
Head Cellular and Molecular Diagnostics, Division Personalized Tumor Therapy, Fraunhofer-Institute for Toxicology and Experimental Medicine ITEM-R, Germany

SIMON LUCAS
Innovation Field Explorer, Merck KGaA, Germany

18:20 **Closing Remarks** / End of Day 1

18:20 - 19:20 **Networking Drinks Reception**

DAY 2 FRIDAY 11TH OCTOBER 2019

08:00 - 08:55 Refreshments

08:55 - 09:00 Morning Chair's Opening Remarks

CLINICAL APPLICATIONS

09:00 - 09:40

KEYNOTE ADDRESS:
DIANA ANDERSON Established Chair, Biomedical Sciences, University of Bradford, UK
A Liquid Biopsy Assay to detect Cancer
There appeared to be no single test to identify cancer in general, but we have developed such an assay. In this modified patented Comet assay, we investigated peripheral lymphocytes from blood of 208 individuals, known as the Lymphocyte Genome Sensitivity (LGS) test. Ninety four individuals were controls. All cancers tested exhibited comparable responses. Analyses of Receiver Operating Characteristic (ROC) curves, of mean log Olive tail moments for cancer alone versus controls alone, the area under the curve was 0.93. By varying the threshold for test positivity, its sensitivity or specificity can approach 100% whilst maintaining acceptable complementary measures. Since lymphocytes in blood only are examined, and the test has been repeated with over 900 individuals with equally valid responses, this is a useful Liquid Biopsy assay.

09:40 - 10:10 **RALPH GRAESER** Senior Translational Medicine Expert, Boehringer Ingelheim
Liquid biopsies on the road to clinical utility
- Use of liquid biopsies in the clinic: diagnostic, prognostic, predictive?
- CTCs vs ctDNA: one or the other – or both?
- CANCER-id – a public-private partnership with the goal to standardize liquid biopsy protocols for clinical use

10:10 - 10:40 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

10:40 - 11:50 Morning Refreshments / Poster Presentations

11:50 - 12:20 **MIKE MAKRIGIORGOS** Professor of Radiation Oncology, Dana Farber Cancer Institute and Harvard Medical School, USA
Novel digital PCR and mutation enrichment technologies for the analysis of clinically relevant DNA alterations in liquid biopsies
With the increasing interest in treatment assessment using liquid biopsy and circulating DNA, sensitive and multiplexed detection of tumor-derived alterations in blood are desirable. We provide novel forms of digital PCR, as well as mutation enrichment-based real time PCR methods that (a) enable several orders of magnitude improvement of detecting mutations or microsatellite instability than currently possible; (b) are highly multiplex-able; (c) reduce cost of analysis. Application in circulating DNA from clinical cancer samples will be presented.

12:20 - 12:50 **JOHN MARTIGNETTI** Professor, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, and Director, Laboratory of Translational Research, Western Connecticut Health Network, USA
A targeted multi-analyte liquid biopsy to identify early stage gynecologic cancers
Overwhelmingly the power and success of "liquid biopsy" has been focused on issues related to advanced disease in already diagnosed patients under active treatment. We demonstrate an approach and the feasibility of using a targeted liquid biopsy approach for detecting early stage gynecologic cancers by combining analysis of both DNA and proteins.

12:50 - 13:20 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

13:20 - 14:20 **Lunch**

14:20 - 14:50 **EVI LIANIDOU** Professor of Analytical Chemistry – Clinical Chemistry, University of Athens, Greece
CTC analysis: Latest advancements and clinical applications
- Liquid biopsy provides a valuable source of biomarkers through simple and minimally invasive serial blood draws and represents a highly dynamic diagnostic, prognostic and theranostic tool for the management of cancer patients.
- Circulating tumor cells (CTCs) are major players in liquid biopsy and their molecular characterization offers an exciting approach to monitor the efficacy of systemic therapies in real-time, unravel the biology of cancer cell dissemination, understand resistance to established therapies and identify gene targets and signalling pathways relevant to therapeutic interventions.
- Single-cell CTC analysis is a powerful tool to understand tumor heterogeneity and the mechanisms involved in cancer progression with potential implications for improving treatment strategies.
- This lecture will be focused on the latest developments in the detection and molecular characterization of CTCs, and their clinical applications in many types of cancer.

15:00 - 15:30 **LUDOVIC BARAULT** Senior Research Associate, Candiola Cancer Institute and the University of Torino, Italy
Prognostic and predictive value of circulating methylated DNA in metastatic colorectal cancer patients treated with regorafenib
- Regorafenib is associated with improved progression free survival (PFS) in a subset of metastatic colorectal cancer (mCRC) patients and no biomarkers of efficacy are available for this drug which is often associated with many toxicities.
- We previously found an association between circulating methylated DNA and outcome in chemotherapy treated mCRC patients and we hypothesized that such biomarker could be used to identify cases most likely to benefit from regorafenib (i.e. patients with PFS longer than 4 months).
- Assessment of pre and on treatment blood samples confirmed the prognostic value of circulating methylated DNA and suggest its use as biomarker for regorafenib since it may predict unresponsiveness to the treatment.

15:20 - 15:50 **ANDREAS HAUSER** Staff Scientist, Ludwig-Maximilians-Universität (LMU), Munich and the Laboratory for Functional Genome Analsis (LAFUGA)
Possibilities of Nanopore Long Read Sequencing in Liquid Biopsy
As sequencing continues to become cheaper and more realtime, more opportunities arise in liquid biopsies. Long Read Nanopore Sequencing offers especially interesting possibilities. In addition to common short reads benefits, like SNP calling, long reads enable cheap assembly of host or pathogen genomes, identification of structural variation, repeat array resolution. Nanopore sequencing specifically also allows for unamplified sequencing, direct RNA sequencing and methylation calling on DNA and RNA. The currently available devices also allow analysis while running making it possible to continuously monitor or stop until detection of specific sequences.

15:50 - 16:20 **HEZEKIAH BLAKE** Director Corporate Development, Ionis (Reserved)

16:20 **Conference Close**

Track Switch
Listen to any talk - Attendees are encouraged to move between Congresses

FLOW CYTOMETRY CONGRESS

UTILIZING FLOW CYTOMETRY AS A TOOL FOR PROGRESSING MEDICAL RESEARCH AND DIAGNOSTIC CAPABILITIES

DAY 1 THURSDAY 10TH OCTOBER 2019

08:00 - 09:00 Registration & Refreshments

08:50 - 09:00 Welcome Address and Morning Chair's Opening Remarks

STRATEGY & TECHNOLOGY

09:00 - 09:40 KEYNOTE ADDRESS
RICHARD SCHEUERMANN Director, Adjunct Professor, J. Craig Venter Institute
Semi-supervised data clustering and machine learning for leukemia diagnosis
The current approach for identifying diagnostic cell populations from cytometry data in clinical labs is based on manual gating analysis, which is subjective and labor-intensive, especially with higher-dimensional complex datasets. Over the last several years, our group and others have developed a suite of computational tools and machine learning for the processing and analysis of cytometry data. To illustrate the potential use of these methods in a clinical diagnostic setting, we will present the results of a pilot project to optimize and apply a selected set of computational and machine learning methods for the automated identification of chronic lymphocytic leukemia (CLL) cells in patient samples

09:40 - 10:20 KEYNOTE ADDRESS:
ANNE WILSON Director of the Flow Cytometry Facility, University of Lausanne (UNIL) Switzerland)
Imaging Flow Cytometry – combining statistically powerful flow cytometry with information rich microscopy
Conventional flow cytometry is a statistically powerful technology used to analyze antigen expression in populations of cells at the single cell level. It however provides little information about cell morphology, interactions between cells and localization of antigens or molecules on or within the cells, or, co-localization of molecules to cytoplasmic or nuclear structures. Imaging Flow cytometry provides all this detailed information and more at the single cell level on large numbers of cells, combining the best features of both conventional flow cytometry and microscopy. This presentation provides examples of the power and diversity of this technology.

10:20 - 10:50 **SENIOR REPRESENTATIVE**
NeoGenomics

10:50 - 12:00 Morning Refreshments / Poster Presentations

12:00 - 12:30 **RACHEL ERRINGTON** Chair and Principle Investigator of the Tissue MicroEnvironment Group Division of Cancer and Genetics, School of Medicine, Cardiff University
Seeing more by targeting less - development of probes, prodrugs and provenance
The development of both fluorescent probes is an important endeavour in cancer research useful for the drug discovery pipeline. Our simple working hypothesis is that the cellular uptake and subcellular localisation of molecules can provide important information on the status of a cell. Core to the Deep-RedAnthraQuinone (DRAQ) probe family is that the spectral-window for both excitation and emission sits in the red (>600nm) thereby making the probe suitable for studies on single cells (2D) through to thick tissue models (3D ie spheroids and organoids). Our key undertaking has been to design molecules that allow us to tune their capacity to label the nucleus versus other cellular compartments providing a greater range of signal readouts, for tracking behaviour and the emergent properties of populations.

12:30 - 13:00 **JANE SRIVASTAVA** Flow Cytometry Facility Manager, South Kensington Campus, Imperial College London
The Development of a Multicolour Antibody Panel for Mouse Bone Marrow Stromal Cells – Challenges and Breakthroughs
- Why is this panel important?
- Why we chose these specific markers and fluorophores
- Some tips for the challenges of working with a large multicolour antibody panel with rare cells
- Final panel considerations and preliminary data
- Future work

13:00 - 13:30 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

13:30 - 14:30 **Lunch**

14:30 - 15:00 **VILMA DECMAN** Associate Director Flow Cytometry, Bristol-Myers Squibb
Implementation of Multi-Parameter Flow Cytometry Assays in Clinical Trials
Flow cytometry is a powerful technique in the research, drug development and clinic as it allows for the examination of multiple targets on various cell subsets from a limited sample size. Its ability to identify and enumerate different cellular markers and track them across time and treatment aids in understanding of disease pathology, toxicological assessment of new drugs and their efficacy. This talk will concentrate on implementation of multi-parameter flow cytometry in clinical trials including:
- Understanding of biomarker needs in development of high-dimensional flow cytometry assays
- Design and optimization of panels; potential pitfalls
- Validation of assay/standardization
- Sample logistics
- New technology platforms

15:00 - 15:30 **VLADIMIR ZHAROV** Professor, Director, University of Arkansas for Medical Sciences, Arkansas Nanomedicine Center
Topic: an in vivo approach to the early photoacoustic detection of infectious diseases and blood conditions

15:30 - 16:00 **60 MINUTE INTERACTIVE WORKSHOP**
Sponsored by Beckman Coulter

16:30 - 17:20 **Afternoon Refreshments** / Poster Presentations

17:20 - 17:50 **CHRIS GROVES** Senior Manager, MedImmune
Topic: standardizing technical practise across labs – developing an automated shared resource library

17:50 - 18:20 **RYAN BRINKMAN** Professor, Medical Genetics, University of British Columbia Distinguished Scientist, BC Cancer CEO, Cytapex Bioinformatics Inc.
Data-driven cytometry
Manual analysis of flow cytometry data is subjective and time consuming. Automated algorithms have reached a level of maturity that enables them to match and, in many cases, exceed the results produced by human experts. The current state-of-the-art will be reviewed though example applications of these algorithms in automating the entire data analysis pipeline. Examples will include automated quality checking at the event and sample level, rapid, robust and reproducible automated gating and biomarker discovery algorithms. The utility of these algorithms will be shown through their application on patient data for basic research, clinical trials and drug discovery.

18:20 **Closing Remarks** / End of Day 1

18:20 - 19:20 **Networking Drinks Reception**

Track Switch
Listen to any talk - Attendees are encouraged to move between Congresses

DAY 2 FRIDAY 11TH OCTOBER 2019

08:15 - 08:55 Refreshments

08:55 - 09:00 Morning Chair's Opening Remarks

CELLULAR ANALYSIS & APPLICATIONS IN ONCOLOGY

09:00 - 09:40

KEYNOTE ADDRESS:
FRANK PREIJERS Radboud University Medical Center, Nijmegen, The Netherlands

From stem cell to blood cell: flow cytometry of the differentiation pathway

Flow cytometry (FCM) is increasingly used in clinical laboratories for diagnosis of various hematological disease. The rapid and sensitive multi-parameter detection renders FCM to a powerful tool to distinguish malignant cells from normal. Pattern recognition of fluorescence expression levels of conjugates and combinations in the various cells activation stages is hereby essential. However, before aberrancies can be established, the normal hematopoiesis must be studied. Bone marrow contains all differentiation stages of hematopoiesis. The maturation can be monitored by changes in immunophenotype, identified by a unique combination of MoAbs. Each antigen is expressed by an appropriate expression pattern during the maturation. Frequently, neoplastic cells possess aberrant immunophenotypes. More or less antigens and antigen expression on different levels can be found in these leukemic cells. This implies that knowledge of the normal cell maturation patterns facilitates recognition of malignant cells. We studied the maturation pathways from stem cells to myeloid, monocytic and erytroid lineage cells using a 10-color NaviosTM (Beckman Coulter) and KaluzaTM analysis software.

09:40 - 10:10 **GARY WARNES** Flow Cytometry Core Facility Manager, Blizard Institute, Barts and London School of Medicine & Dentistry, Queen Mary London University

Topic: identifying new forms of cell death – using flow cytometry to explore cell fate

- RIP3 and Caspase-3 intracellular labelling with a fixable live/dead probe allows the flow cytometric detection of necroptosis (RIP3high+ve/Caspase-3-ve) , apoptosis (RIP3-ve/Caspase-3+ve) and RIP1-dependent apoptosis (RIP3+ve/Caspase-3+ve)
- Further labelling with LC3B allows the detection of autophagic cells
- Additional labelling with H2AX and PARP allows further identification of DNA damage, hyper-action of PARP and parthanatos
- Incidences of RCD were modulated by the use of zVAD and Necrostain-1
- Autophagy was shown to protect cells by reducing DNA damage
- Use of MitoTracker and violet live cell caspase probe allows the identification of necroptosis and apoptosis in unfixed cells
- Additional use of fixable probes for mitochondrial function and Reactive Oxygen Species (ROS) extends the number of identifiable cell death populations to 500

10:10 - 10:40 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

10:40 - 11:50 **Morning Refreshments** / Poster Presentations

11:50 - 12:20 **DAVID BAKER** Senior Research Scientist, AstraZeneca

Starting up clinical trials with TCR-modified T cells in solid cancers

- The high-throughput flow cytometry capability at AZ and examples of how this has been used.
- Applications of high-throughput flow cytometry in immuno-oncology projects (assays such as T-cell proliferation, activation, tumour killing assays).

12:30 - 13:00 **STEPHANIE TRAUB** Cancer Research UK

Applications of flow cytometry in early phase oncology trials

The presentation will outline the use of flow cytometry in early phase clinical development with relevant examples of commonly encountered challenges and suggested solutions.

12:50 - 13:20 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

13:20 - 14:20 **Lunch**

14:20 - 14:50 **FRIDTJOF LUND-JOHANSEN** Head of flow cytometry core facility, Oslo University Hospital, Norway

Topic: developing a GUCY2C-Targeted Adoptive T Cell Therapy

Proteomics is still a small discipline where the research front is driven by a few laboratories with unrestricted access to mass spectrometry (MS). With MAP, we put the power of proteomics into the hands of flow cytometry (FCM) users. Bead-based arrays with a multiplexing capacity up to 5000 provide the convenience and throughput needed to take proteomics to the next level. The challenge lies in changing the mindset that keeps the western blot on top of the list of the most popular antibody applications. The FCM version is called Western-MAP and yields results for thousands of antibodies in parallel. In Native-MAP, proteins are separated by size exclusion chromatography for large-scale analysis of protein complexes. Thus, MAP turns the flow cytometer into a high throughput proteomics machine.

14:50 - 15:20 **PIA KVISTBORG** Junior Group Leader, NKI Amsterdam (Reserved)

Topic: analysing t cells for neo-antigen specificity

14:50 - 15:20 **SENIOR REPRESENTATIVE** Invitation Out

15:50 **Closing Remarks** / Conference Close

NOVEL ANTIBODY THERAPEUTICS CONGRESS

THE LATEST IN SCIENTIFIC, TECHNOLOGICAL AND BUSINESS TRENDS ADVANCING ANTIBODY AND PROTEIN THERAPEUTICS

DAY 1 THURSDAY 10TH OCTOBER 2019

08:00 - 08:50 Registration & Refreshments

08:50 - 09:00 Welcome Address and Morning Chair's Opening Remarks

ANTIBODIES FOR ONCOLOGY

09:00 - 09:40

KEYNOTE ADDRESS:
RENE HOET CSO, Imcheck Therapeutics
Development of a next generation immune checkpoint modulator towards the clinic; a humanized BTN3A antibody (ICT01) activating gamm9delta2 T cells

ImCheck Therapeutics is advancing the first activating butyrophilin BTN3A (CD277) antibody towards the clinic. The humanized antibody to BTN3A, ICT01, specifically activates human gamma9delta2 T-cells in-vitro and in-vivo and is planned to enter phase I studies early 2020. Additionally, therapeutic antibodies against 5 novel butyrophilins are currently validated. This opens a completely new space clearly different from the current B7/CD28 superfamily targets and has the potential to become the next generation immune checkpoint modulators.

09:40 - 10:20

KEYNOTE ADDRESS:
RAKESH DIXIT VP, Research & Development and Global Head Biologics Safety, MedImmune
Cancer Bispecific Biologics: Current Status and Learnings From Successes and Failures

- Overview of landscape of bispecifics targeting cancers
- Preclinical and clinical landscape of bispecifics in oncology
- Five rights of bispecifics: A case study of unique immune checkpoints targeting bispecific
- Learnings from success and failures of bispecifics

10:20 - 10:50 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

10:50 - 12:00 Morning Refreshments / Poster Presentations

12:00 - 12:30 **SOPHIA KARAGIANNIS** Reader in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, King's College London
Triple Negative Breast Cancer targeted therapy with anti-Folate Receptor alpha antibodies

Employing a multi-omics approach we show that the folate carrier Folate Receptor alpha (FRα) is upregulated in triple negative breast carcinomas and that expression of molecules involved in the folate metabolism are dysregulated. FRα is expressed in post-neoadjuvant chemotherapy residual disease, and participates in cancer cell signaling and cancer cell growth. We demonstrate that FRα and the folate cascade could be targeted with specific inhibitors. Furthermore, FRα may present a target for antibody immunotherapy that primes an Fc-mediated anti-tumor immune response, and an antibody-drug conjugate approach that can deliver a pathway inhibitor to FRα-expressing cells. These findings may point to a new treatment avenue for patients with triple negative breast cancer.

12:30 - 13:00 **JENNY KARLSSON** Head of TCR Biochemistry, Bayer
Targeted Thorium Conjugates: Novel first in class targeted alpha therapy

- Targeted thorium conjugates (TTCs) represent a new class of therapeutic radiopharmaceuticals for the targeted alpha therapy (TAT) of cancer.
- TAT has become an established modality in the treatment of metastatic castration-resistant prostate cancer following the approval of radium-223 dichloride.
- TATs are highly cytotoxic due to the high linear energy transfer of the alpha-particle emitting radionuclide which induces complex DNA double-strand breaks in the targeted tumor cell.
- TTCs consist of a targeting moiety, a chelator covalently linked via an amide bond to the antibody and thorium-227 complexed to the chelator with high affinity.
- Important advantages of TTCs are the lack of known resistance mechanisms to alpha-particle emission and their ability to also kill non-dividing cells.
- Preclinical in vitro and in vivo data will be presented.

13:00 - 13:30 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

13:30 - 14:30 **Lunch**

14:30 - 15:00 PANEL DISCUSSION:
Next Generation Antibodies: beyond bispecifics
SYD JOHNSON VP, Antibody Engineering & Consultant, Macrogenics
RAKESH DIXIT VP, Research & Development and Global Head Biologics Safety, MedImmune

15:00 - 15:30 **FRANCESCO GALIMI** Global Product General Manager, Early Development, Amgen
Bi-specific T-cell Engagers (BiTE®) in Hematological Malignancies

The bispecific T-cell engager (BiTE®) blinatumomab (Blincyto®) has recently been approved for Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It consists of two single chain variable fragments (scFvs) specific for CD19 present on the B-cell lineage, and CD3 expressed on almost all T cells. Based on the potent anti-tumor activity of Blincyto® in B-cell malignancies, BiTE® antibody constructs directed against other target antigens are being tested in a number of malignancies, in particular acute myeloid leukemia and multiple myeloma. We will review the ongoing activities in this field.

16:00 - 16:15 **SENIOR REPRESENTATIVE**
Twist Bioscience

16:15 - 16:30 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

16:30 - 17:20 Afternoon Refreshments / Poster Presentations

17:20 - 17:50 **CHRISTIAN BREUNIG** Group Leader Biomarker & Cell Biology, Heidelberg Pharma
POLR2A as a putative predictive biomarker for treatment with Amanitin-based ADCs

Heidelberg Pharma develops Antibody Targeted Amanitin Conjugates (ATACs), a new class of Antibody-Drug Conjugates with the cyclic peptide amanitin as the toxic payload. Amanitin blocks the cellular transcription process by specifically binding to the eukaryotic RNA polymerase II. POLR2A, the largest subunit in the human RNA polymerase II complex, is located on chromosome 17p13.1 and in close proximity to TP53. A chromosome 17p deletion is present in any cancer patients correlating with poor survival. Furthermore, we observed that a deletion of POLR2A significantly enhanced treatment efficacy of ATACs in different in vivo models. Based on these observations, Heidelberg Pharma proposes POLR2A as a putative biomarker to identify patients that would benefit the most from treatment with ATACs

17:50 - 18:20 **JOHAN NILVEBRANT** Researcher, School of Engineering Sciences in Chemistry, Biotechnology and Health , KTH
Antibody libraries based on an autonomous human variable domain

Antibodies are tremendously useful for biotechnological applications, diagnostics and therapy. However, their complex architecture has spurred interest in smaller derivatives that can retain the targeting specificity and be more easily produced. We have constructed highly diverse (>1010) libraries based on an autonomous human variable heavy (VH) domain and used these libraries to select specific binders to the human Eph receptor family. Our aim is to use these binders to develop novel tools for specific investigation of blocking or activation of specific Eph receptor homo or heterodimers. Moreover, structural evaluations of first and second-generation binders to EphA1, which have been identified after stress selections on phage, illustrate how VH domains can be stabilized via tailored CDR mutagenesis.

18:20 **Closing Remarks** / End of Day 1

18:20 - 19:20 **Networking Drinks Reception**

Track Switch
Listen to any talk - Attendees are encouraged to move between Congresses

DAY 2 FRIDAY 11TH OCTOBER 2019

08:15 - 08:55 Refreshments

08:55 - 09:00 Morning Chair's Opening Remarks

IMMUNO-ONCOLOGY FORMATS

09:00 - 09:40 KEYNOTE ADDRESS:
JUSTIN SCHEER Director, Antibody Engineering, Boehringer-Ingelheim (Reserved)
Topic: developing novel checkpoint inhibitors

09:40 - 10:10 **NICOLAS POIRIER** CSO, OSE Immunotherapeutics
BiCKI: a novel Bispecific checkpoint inhibitor platform
- A proprietary transformative technology restating the current anti-PD-(L)1 standard of care.
- An engineered anti-PD-1 bispecific platform to extend the spectrum of patients responding to immunotherapies.
- BiCKI is the 2nd generation of PD-x inhibitors to increase the efficacy in hard to treat tumor types by addressing untapped immune evasion mechanisms.
- OSE's armed anti-PD-1 bispecifics are paving the way to reinstate sustained adaptive and innate immune responses.

10:10 - 10:40 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

10:40 - 11:50 Morning Refreshments / Poster Presentations

11:50 - 12:20 **ROMAN IVANOV** Vice-President, R&D, BIOCAD
Engaging multiple cell populations within immune system with a single mAb: designing Swiss Army knives to fight cancer
- PDL1/CD47 mAb: restoring Teff response and phagocytosis
- PD1/GITR mAb: shifting the Teff/Treg cell balance
- IL15/PD1 mAb: potentiating Teff and NK responses
- Overcoming stability and manufacturability issues
- Cell-based assays for IO bispecifics
- Selection of in vivo models for IO bispecifics

12:20 - 12:50 **JOHN DESJARLAIS** Senior Vice President, Research and Chief Scientific Officer, Xencor (Reserved)
Topic: Advancing t cell engaging antibodies for immuno-oncology

12:50 - 13:20 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

13:20 - 14:20 **Lunch**

14:20 - 14:50 **SONIA QUARATINO** Chief Medical Officer, Kymab
Novel antibodies beyond PD-1 therapy for cancer immunotherapy

14:50 - 15:20 **SHIRLEY PETERS** Principal Scientist, UCB
An engineered IgG1-IgM tp fusion for enhanced CDC activity
- IgG1-IgM tp fusion promote IgG1 hexamerisation
- Engineering tp fusion leads to on-target hexamerisation.
- On-target hexamerisation results in enhanced C1q recruitment which translates to enhanced CDC activity.

15:20 - 15:50 **EMMANUEL NORMANT** VP Preclinical Sciences, TG Therapeutics New York
Novel multi-drug immuno-oncology and targeted thearpy combinations lead to synergy in preclinical models of B-cell malignancies
- Drug combinations are critical for efficacy in oncology. TG Therapeutics is building a "combinable" pipeline in order to increase the depth of response, decrease the instances of resistance, and tackle financial toxicity.
- The presentation focuses on datasets from in vitro and in vivo preclinical models that demonstrates synergy. The drugs used are the anti-CD20 antibody ublituximab, the PI3K inhibitor umbralisib, and the novel CD47-CD19 bispecific antibody TG-1801.
- We show here that targeting the innate CD47 checkpoint increases the efficacy of antibody-dependent cellular toxicity (ADCC) and phagocytosis (ADCP) driven by the anti-CD20 antibody ublituximab.
- The anti-tumor activity of the ublituximab and umbralisib "U2" combination is also enhanced with the anti-CD47 bispecific antibody, TG-1801, warranting clinical trial evaluating this triple-therapy.

15:50 - 16:20 **STEFAN GLÜCK** VP GMA, Celgene (Reserved)
Topic: Engineering a novel check point blockade

16:20 **Conference Close**

ADOPTIVE CELL TRANSFER CONGRESS

EXAMINING THE LATEST ADVANCES IN CAR AND TCR THERAPIES

DAY 1 THURSDAY 10TH OCTOBER 2019

08:00 - 09:00 Registration & Refreshments

08:50 - 09:00 Welcome Address and Morning Chair's Opening Remarks

IMMUNO-ONCOLOGY FORMATS

09:00 - 09:40

KEYNOTE ADDRESS
JOHN MAHER Senior Research Fellow, King's College London
T4 Pan-ERB-Targeted CAR T-Cell Immunotherapy of Head and Neck Cancer: Phase I Trial Results

- A CAR has been engineered using a promiscuous ligand that engages 8 distinct ErbB dimer species
- Phase 1 evaluation has been initiated in patients with head and neck cancer, using intra-tumoural delivery and phased dose escalation to mitigate risk
- Fourteen patients have been safely treated to date, at doses of up to 1Bn cells, without DLTs and with an efficacy signal evident.

09:40 - 10:20

KEYNOTE ADDRESS:
LAURENT POIROT VP Immunology Department, Cellectis
A TALEN platform for the engineering of allogeneic CAR T-cells

- TALEN-mediated gene editing is highly efficacious, precise and specific
- Incorporation of gene-editing in a robust manufacturing process is leveraged to maximize the potential benefits of allogeneic approach in haematological malignancies
- The complexicity of genome editing can now be increased to tackle even more difficult cancers.

10:20 - 10:50 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

10:50 - 12:00 Morning Refreshments / Poster Presentations

12:00 - 12:30 **ROBERT HAWKINS** CEO Immetacyte Ltd /Honorary Professor Medical Oncology, University of Manchester
Developing TIL based treatment for solid tumours

- Background to TIL therapy and potential benefits in solid tumours
- Clinical results in melanoma
- Pre-clinical data in other tumours
- Engineering TIL to produce second generation products

12:30 - 13:00 **STEFFEN WALTER** CSO, Immatics US
Beyond CD19: multi-targeted adoptive cell therapy for solid tumors
CAR-T therapies are revolutionizing the treatment of haematologic malignanices but have shown limited success in solid tumors. TCR-T based approaches have delivered historically better response rates in solid tumors, but are critically lacking validated targets for large cancer indications. XPRESIDENT® is the leading platform for the discovery of novel targets for all types of TCR-T therapy. XCEPTOR® is a leading platform for the discovery of affinity-tuned, safer T-cell receptors. Together, these technologies have enabled a pipeline of clinical-stage adoptive cell therapy programs, namely ACTolog® and ACTengine®, which include one of the first clinical trials to apply multi-targeted TCR-T to solid tumor patients

13:00 - 13:30 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

13:30 - 14:30 **Lunch**

14:30 - 15:00 **ROBERT IGARASHI** CSO, Cytosen Therapeutics
NK Cell Stimulation Using Membrane Bound IL-21

- Addressing the needed for an effective and robust methodology for efficient production of large doses of NK cells with high anti-tumor potency
- NK cell stimulation for production of high dosages and repeat dosages of highly potent NK cells.
- Advancing clinical development of NK cell therapeutics for treatment of AML in the near future

15:00 - 15:30 **BOB VALAMEHR** Vice President of Cancer Immunotherapy, Fate Therapeutics
Topic: the potential of natural killer cells as novel therapeutics

15:30 - 16:00 **SENIOR REPRESENTATIVE** Glycostem (Reserved)
Topic: Engineering NK cell formats

16:30 - 17:20 **Afternoon Refreshments** / Poster Presentations

17:20 - 17:50 **KAI CHAN** VP EU Head of Medical Affairs, Bellicum Pharmaceuticals
Rivogenlecleucel (Rivo-cel™): Making a Difference in Pediatric Leukemias & Orphan Blood Disorders

17:50 **Closing Remarks** / End of Day 1

17:50 - 18:50 **Networking Drinks Reception**

DAY 2 FRIDAY 11TH OCTOBER 2019

08:15 - 08:55 Refreshments

08:55 - 09:00 Morning Chair's Opening Remarks

09:00 - 09:40

KEYNOTE ADDRESS:
DOLORES SCHENDEL CEO and CSO, Medigene
TCR-modified adoptive cell therapies: Innovation for the future

- First generation TCR-Ts are in numerous clinical studies
- Innovations will alter new generation TCR-Ts going forward
- Innovations have potential to change safety and efficacy of cellular products
- Innovations can improve manufacturing and reduce cost of goods

09:40 - 10:10

KEYNOTE ADDRESS:
CEDRIK BRITTEN Head of Oncology Cell Therapy Research Unit (OCT RU), GSK
Understanding drivers of clinical pharmacology for engineered T cell products?

- Selection of antigen(s) for CAR/TCR T cells
- Design of immune-receptor constructs
- Efficacy-enhancement technologies to drive benefit in patients with solid cancer
- Selection of dose for CAR/TCR-T
- Update on clinical development of GSK3377794 (NY-ESO TCR-T)

10:10 - 10:40 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

10:40 - 11:50 **Morning Refreshments** / Poster Presentations

11:50 - 12:20 **MONA WELSCHOF** Director Clinical Development, Zelluna Therapeutics
Starting up clinical trials with TCR-modified T cells in solid cancers

- Introduction of Zelluna's TCR-modified T cell Approach
- Pinpointing the importance of understanding the regulatory pathways and early interactions with regulatory authorities
- Discussion of the various operational challenges in setting up adoptive cell therapy trials

12:30 - 13:00 **VICKI COUTINHO** Senior Director Regulatory Affairs, Autolus (Reserved)
Topic: exploring the regulatory landscape for cell therapies

12:50 - 13:20 **SOLUTION PROVIDER PRESENTATION**
For sponsorship opportunities contact Nick Best or Tony Couch:
Sponsorship@globalengage.co.uk

13:20 - 14:20 **Lunch**

14:20 - 14:50 **PEGGY SOTIROPOULOU** Director, Research & Development, Celyad
Combining Innate and Adaptive Immunity: Using NK Receptors for CAR T Cell Therapy

- Leveraging NKG2D receptor for cancer immunotherapy
- Autologous NKG2D-based CAR T cells to target hematopoietic and solid tumours
- Non-gene edited allogeneic NKG2D-based CAR T cell therapy

14:50 - 15:20 **ADAM SNOOK** Assistant Professor of Pharmacology and Experimental Therapeutics, Thomas Jefferson University
GUCY2C CAR-T cell Therapy for Metastatic Colorectal Cancer
Guanylyl cyclase C (GUCY2C) is a cell surface receptor expressed in the apical brush border membrane of intestinal epithelial cells and an emerging target for cancer immunotherapy. GUCY2C is expressed throughout the intestinal tumorigenesis processes from benign adenomas to metastatic adenocarcinomas in nearly all colorectal cancers, making it an attractive target for cancer immunotherapy. Here, I describe our approach to develop an adoptive cell therapy (ACT) paradigm employing T cells engineered to express a chimeric antigen receptor (CAR) targeting GUCY2C. In preclinical studies, GUCY2C CAR-T cells eliminated bulky colorectal cancer metastases, without toxicity, positioning this therapy for translation to clinical studies in patients with colorectal cancer, the 3rd leading cause of cancer-related death in the world.

15:20 - 15:50 **CHRIS KLOSS** Scientist, Janssen (Reserved)
Topic: advancing CAR T products for targeting solid tumors to the clinic

15:50 **Closing Remarks** / Conference Close

TMB & NEOANTIGENS CONGRESS	LIQUID BIOPSIES CONGRESS	FLOW CYTOMETRY CONGRESS	NOVEL ANTIBODY THERAPEUTICS CONGRESS	ADOPTIVE CELL TRANSFER CONGRESS
08:00-09:00 Registration & Refreshments				
KEYNOTE ADDRESS: **RAJIV RAJA** Director, Oncology Translational Medicine, AstraZeneca, USA **ctDNA-based biomarkers in immuno-oncology drug development: opportunities and challenges**	KEYNOTE ADDRESS: **MATT TRAU** Professor of Chemistry, Deputy Director and Co-Founder of AIBN, University of Queensland, Australia **A universal biomarker for cancer: Are we there yet?**	KEYNOTE ADDRESS: **RICHARD SCHEUERMANN** Director, Adjunct Professor, J. Craig Venter Institute **Semi-supervised data clustering and machine learning for leukemia diagnosis**	KEYNOTE ADDRESS: **RENE HOET** CSO, Imcheck Therapeutics **Development of a next generation immune checkpoint modulator towards the clinic; a humanized BTN3A antibody (ICT01) activating gamm9delta2 T cells**	KEYNOTE ADDRESS: **JOHN MAHER** Senior Research Fellow, King's College London **T4 Pan-ERB-Targeted CAR T-Cell Immunotherapy of Head and Neck Cancer: Phase I Trial Results**
KEYNOTE ADDRESS: **CHRISTOPHE LE TOURNEAU** Head, Department of Drug Development and Innovation (D3i), Institut Curie, France **Optimising patient benefit whilst reducing toxicity risk**	KEYNOTE ADDRESS: **SIMON LUCAS** Innovation Field Explorer, Merck KGaA **Enabling Liquid Biopsy in Cancer and Beyond**	KEYNOTE ADDRESS: **ANNE WILSON** Director of the Flow Cytometry Facility, University of Lausanne (UNIL) Switzerland) **Imaging Flow Cytometry – combining statistically powerful flow cytometry with information rich microscopy**	KEYNOTE ADDRESS: **RAKESH DIXIT** VP, Research & Development and Global Head Biologics Safety, MedImmune **Cancer Bispecific Biologics: Current Status and Learnings From Successes and Failures**	KEYNOTE ADDRESS: **LAURENT POIROT** VP Immunology Department, Cellectis **A TALEN platform for the engineering of allogeneic CAR T-cells**
SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:
10:50-12:00 Morning Refreshments / One-to-One Meetings / Poster Presentations				
WILL SPOONER Commercial Programme Delivery Lead, Genomics England, UK **Will whole genome sequencing of fresh frozen tumour material become the assay of choice for cancer molecular diagnostics?**	**ANDERS STAHLBERG** Associate Professor, University of Gothenburg, Sweden **Considerations when analyzing cell-free tumor DNA**	**RACHEL ERRINGTON** Chair and Principle Investigator of the Tissue MicroEnvironment Group Division of Cancer and Genetics, School of Medicine, Cardiff University **Seeing more by targeting less - development of probes, prodrugs and provenance**	**SOPHIA KARAGIANNIS** Reader in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, King's College London **Triple Negative Breast Cancer targeted therapy with anti-Folate Receptor alpha antibodies**	**ROBERT HAWKINS** Cancer Research UK Professor/ Honorary Consultant in Medical Oncology, University of Manchester/ Christie Hospital **Topic: ATTACK and ATTRACT platforms – approaches to engineering cellular therapies**
JENS KRINGELUM Director, Genomic Immuno Oncology, Evaxion Biotech, Denmark **Using Artificial Intelligence to accelerate Immunotherapy**	**AN HENDRIX** Assistant Professor, University of Ghent, The Netherlands **Standardized analysis of extracellcular vesicles in liquid biopsies**	**JANE SRIVASTAVA** Flow Cytometry Facility Manager, South Kensington Campus, Imperial College London **The Development of a Multicolour Antibody Panel for Mouse Bone Marrow Stromal Cells – Challenges and Breakthroughs**	**JENNY KARLSSON** Head of TCR Biochemistry, Bayer **Targeted Thorium Conjugates: Novel first in class targeted alpha therapy**	**STEFFEN WALTER** CSO, Immatics US **Beyond CD19: multi-targeted adoptive cell therapy for solid tumors**
SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:
13:30-14:30 Lunch				
PAMELA CARROLL Senior Vice President, Scientific Strategy, Genocea Biosciences, USA **ATLAS™ – A Critical Tool in Finding True Neoantigens**	**DOLORES CAHILL** Professor of Translational Science, University College Dublin, Ireland **Innovation in Research: From Protein Array to Companion Diagnostics to Profiling of Adverse Events**	**FREDRIK WALLBERG** (Reserved) Facility Manager, Institute for Cancer Research **Topic: developing imaging technology for analysis of cell health**	PANEL DISCUSSION: **Next Generation Antibodies: beyond bispecifics** **SYD JOHNSON** VP, Antibody Engineering & Consultant, MacroGenics **RAKESH DIXIT** VP, Research & Development and Global Head Biologics Safety, MedImmune	**ROBERT IGARASHI** CSO, Cytosen Therapeutics **NK Cell Stimulation Using Membrane Bound IL-21**
ELISA SCARSELLI CSO, Nouscom, Italy **Combined treatment with checkpoint blockade and Adenovirus vaccine targeting multiple neoantigens eradicates large tumors in mice**	**JEAN-YVES PIERGA** Institut Curie, Department of Medical Oncology and Circulating Tumor Biomarkers Laboratory, SiRIC, Université Paris Descartes, France **Clinical utility of CTC and ctDNA in metastatic and neo/adjuvant setting of breast cancer**	**VILMA DECMAN** Associate Director Flow Cytometry, Bristol-Myers Squibb **Implementation of Multi-Parameter Flow Cytometry Assays in Clinical Trialsh**		**BOB VALAMEHR** (Reserved) Vice President of Cancer Immunotherapy, Fate Therapeutics **Topic: the potential of natural killer cells as novel therapeutics**
AGNETE FEDRIKSEN President and CSO, Vaccibody, Norway **Considerations and experiences from taking a fully personalized targeted cancer neoantigen DNA vaccine into the clinic**	**IWANKA KOZAREWA** Associate Principal Scientist, Translational Medicine, AstraZeneca, UK	**VLADIMIR ZHAROV** Professor, Director, University of Arkansas for Medical Sciences, Arkansas Nanomedicine Center **Topic: an in vivo approach to the early photoacoustic detection of infectious diseases and blood conditions**	**FRANCESCO GALIMI** Global Product General Manager, Early Development, Amgen **Bi-specific T-cell Engagers (BiTE®) in Hematological Malignancies**	**SENIOR REPRESENTATIVE** (Reserved) Glycostem **Topic: Engineering NK cell formats**
SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:
16:30-17:20 Afternoon Refreshments / One-to-One Meetings / Poster Presentations				
SARAH MISSEL Director, Translational Development, R&D Strategy and Communications, Immatics, Germany **Tailor-made immunotherapies: Integrating non-mutated and neoantigens into highly personalized immunotherapy approaches** **KAIDRE BENDJAMA** Project Leader, Personalized Cancer Vaccination, Transgene **Viral-based vaccine for cancer neoantigen vaccination**	PANEL DISCUSSION: **Translating liquid biopsies into routine care** **KATARZYNA WITKOWSKA** Commercial Partnerships Manager, Genomics England, UK **KAREN SPINK** Innovation Lead – Precision Medicine, Innovate UK **ALEXANDRE HARLÉ** Assistant Professor, Molecular Biologist, Institut de Cancérologie de Lorraine, France **IWANKA KOZAREWA** Senior Scientist, AstraZeneca, UK **BERNHARD POLZER** Head Cellular and Molecular Diagnostics, Division Personalized Tumor Therapy, Fraunhofer-Institute for Toxicology and Experimental Medicine ITEM-R, Germany **SIMON LUCAS** Innovation Field Explorer, Merck KGaA, Germany	**CHRIS GROVES** Senior Manager, MedImmune **Topic: standardizing technical practise across labs – developing an automated shared resource library** **RYAN BRINKMAN** Professor, Medical Genetics, University of British Columbia Distinguished Scientist, BC Cancer CEO, Cytapex Bioinformatics Inc. **Data-driven cytometry**	**CHRISTIAN BREUNIG** Group Leader Biomarker & Cell Biology, Heidelberg Pharma **POLR2A as a putative predictive biomarker for treatment with Amanitin-based ADCs** **JOHAN NILVEBRANT** Researcher, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH **Antibody libraries based on an autonomous human variable domain**	**KAI CHAN** VP EU Medical Affairs, Bellicum Pharmaceuticals **Rivogenlecleucel (Rivo-cel™): Making a Difference in Pediatric Leukemias & Orphan Blood Disorders**
18:20 Chair's Closing Remarks / End of Day One				
18:20-19:20 Networking Drinks Reception				

TMB & NEOANTIGENS CONGRESS	LIQUID BIOPSIES CONGRESS	FLOW CYTOMETRY CONGRESS	NOVEL ANTIBODY THERAPEUTICS CONGRESS	ADOPTIVE CELL TRANSFER CONGRESS
08:15-09:00 Refreshments				
KEYNOTE ADDRESS: **GEORGE VASMATZIS** Co-director of the Biomarker Discovery Program, Associate Professor, Department of Molecular Medicine, Mayo Clinic, USA **Chromoplexis and chromothripsis can increase neoantigen load**	KEYNOTE ADDRESS: **DIANA ANDERSON** Established Chair, Biomedical Sciences, University of Bradford, UK **A Liquid Biopsy Assay to detect Cancer**	KEYNOTE ADDRESS: **FRANK PREIJERS** Radboud University Medical Center, Nijmegen, The Netherlands **From stem cell to blood cell: flow cytometry of the differentiation pathway**	KEYNOTE ADDRESS: **JUSTIN SCHEER** (Reserved) Director, Antibody Engineering, Boehringer-Ingelheim **Topic: developing novel checkpoint inhibitors**	KEYNOTE ADDRESS: **DOLORES SCHENDEL** CEO and CSO, Medigene **TCR-modified adoptive cell therapies: Innovation for the future**
KEYNOTE ADDRESS: **EUN-ANG RAIBER-MOREAU** Associate Principal Scientist, AstraZeneca, UK **The promise and challenge of TMB in the clinics for immunotherapy**	KEYNOTE ADDRESS: **RALPH GRAESER** Senior Translational Medicine Expert, Boehringer Ingelheim **Liquid biopsies on the road to clinical utility**	KEYNOTE ADDRESS: **GARY WARNES** Flow Cytometry Core Facility Manager, Blizard Institute, Barts and London School of Medicine & Dentistry, Queen Mary University London **Topic: identifying new forms of cell death – using flow cytometry to explore cell fate**	**NICOLAS POIRIER** CSO, OSE Immunotherapeutics **BiCKI: a novel Bispecific checkpoint inhibitor platform**	**CEDRIK BRITTEN** Head of Oncology Cell Therapy Research Unit (OCT RU), GSK **Understanding drivers of clinical pharmacology for engineered T cell products?**
SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:
10:40-11:50 Morning Refreshments / One-to-One Meetings / Poster Presentations				
TEDD HUPP Chair of Cancer Research, University of Edinburgh, UK **Developing proteogenomcis platforms in cancers of high unmet clinical need**	**MIKE MAKRIGIORGOS** Professor of Radiation Oncology, Dana Farber Cancer Institute and Harvard Medical School, USA **Novel digital PCR and mutation enrichment technologies for the analysis of clinically relevant DNA alterations in liquid biopsies**	**DAVID BAKER** Senior Research Scientist, AstraZeneca **Starting up clinical trials with TCR-modified T cells in solid cancers**	**ROMAN IVANOV** Vice-President, R&D, BIOCAD **Engaging multiple cell populations within immune system with a single mAb: designing Swiss Army knives to fight cancer**	**MONA WELSCHOF** Director Clinical Development, Zelluna Therapeutics **Starting up clinical trials with TCR-modified T cells in solid cancers**
ANDREAS WEINHÄUSEL Thematic Coordinator, Molecular Diagnostics, AIT – Austrian Institute of Technology, Austria **PepPipe – an immunomics workflow elucidating antigenic peptide biomarker signatures for minimal invasive diagnostics**	**JOHN MARTIGNETTI** Professor, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, and Director, Laboratory of Translational Research, Western Connecticut Health Network, USA **A targeted multi-analyte liquid biopsy to identify early stage gynecologic cancers**	**STEPHANIE TRAUB** Cancer Research UK **Applications of flow cytometry in early phase oncology trials**	**JOHN DESJARLAIS** (Reserved) Senior Vice President, Research and Chief Scientific Officer, Xencor **Topic: Advancing t cell engaging antibodies for immuno-oncology**	**VICKI COUTINHO** (Reserved) Senior Director Regulatory Affairs, Autolus **Topic: exploring the regulatory landscape for cell therapies**
SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:	SOLUTION PROVIDER PRESENTATION:
13:20-14:20 Lunch				
ASTRID VISSER Business Development Manager, Sanquin, The Netherlands **Application of in vitro tools that improve selection of (neo)epitopes and characterize T cell responses**	**EVI LIANIDOU** Professor of Analytical Chemistry – Clinical Chemistry, University of Athens, Greece **CTC analysis: Latest advancements and clinical applications**	**FRIDTJOF LUND-JOHANSEN** Head of flow cytometry core facility, Oslo University Hospital, Norway **Topic: developing a GUCY2C-Targeted Adoptive T Cell Therapy**	**SONIA QUARATINO** Chief Medical Officer, Kymab **Novel antibodies beyond PD-1 therapy for cancer immunotherapy**	**PEGGY SOTIROPOULOU** Director, Research & Development, Celyad **Combining Innate and Adaptive Immunity: Using NK Receptors for CAR T Cell Therapy**
TIM FUGMANN Head of Precision Medicine, Philochem, Switzerland **Profiling of neo-antigens presented by cancer cells facilitate patient stratification and development of potent anti-tumor therapies**	**LUDOVIC BARAULT** Senior Research Associate, Candiola Cancer Institute and the University of Torino, Italy **Prognostic and predictive value of circulating methylated DNA in metastatic colorectal cancer patients treated with regorafenib**	**PIA KVISTBORG** (Reserved) Junior Group Leader, NKI Amsterdam **Topic: analysing t cells for neo-antigen specificity**	**SHIRLEY PETERS** Principal Scientist, UCB **An engineered IgG1-IgM tp fusion for enhanced CDC activity**	**ADAM SNOOK** Assistant Professor of Pharmacology and Experimental Therapeutics, Thomas Jefferson University **GUCY2C CAR-T cell Therapy for Metastatic Colorectal Cancer**
KUMAR KARYAMPUDI (Reserved) Director, Translational Science, Iovance, USA **Title TBC**	**ANDREAS HAUSER** Staff Scientist, Ludwig-Maximilians-Universität (LMU), Munich and the Laboratory for Functional Genome Analsis (LAFUGA) **Possibilities of Nanopore Long Read Sequencing in Liquid Biopsy**	**SENIOR REPRESENTATIVE** (Invitation Out) **Title TBC**	**EMMANUEL NORMANT** Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics New York **Novel multi-drug immuno-oncology and targeted thearpy combinations lead to synergy in preclinical models of B-cell malignancies** **STEFAN GLÜCK** (Reserved) VP GMA, Celgene **Topic: Engineering a novel check point blockade**	**CHRIS KLOSS** (Reserved) Scientist, Janssen **Topic: advancing CAR T products for targeting solid tumors to the clinic**
16:20 Chair's Closing Remarks / Conference Close				

London Heathrow Marriott Hotel
Bath Road, Heathrow Airport Hayes,
UB3 5AN, United Kingdom
www.postillionhotels.com/en-gb/conferenties-events/rotterdam-convention-centre

Located less than half a mile away from the Heathrow Airport, this four-star deluxe hotel offers comfortable, noise-free accommodations and is near attractions such as Legoland and Windsor Castle. Modern and vibrant, discover the culinary delights and more in the London Heathrow Marriott.

EVENT SPONSORS

Diamond Sponsor

Platinum Sponsor

Gold Sponsors

Bronze Sponsor

Exhibitors

Content Sponsors

Supporters

SPONSORSHIP AND EXHIBITION OPPORTUNITIES AVAILABLE

For more details contact Nick Best or tony couch at sponsorship@globalengage.co.uk or call +44 (0)1865 849841



OVERVIEW

350+ ATTENDEES

100+ SPEAKERS

35 EXHIBITORS

SECTOR



Pharma / Biotech

Academic

Technology

Service Provider

JOB ROLE

Senior Scientist

CXO / Senior Management

Business Dev

Professor / Researcher

PRICING PLANS

Industry Fee £999

Academic/Not for Profit £499

Solution Provider fee £1,499

This fee applies to organisations offering services and/or business & technology solutions and also to business consultants.

EARLY BOOKING DISCOUNTS

25% off all prices for bookings made in July

15% off all prices for booking made in August

10% of all prices for bookings made in September

DON'T DELAY, BOOK YOUR PLACE TODAY!

Places are limited and are based on a first come, first served basis so to avoid disappointment contact us today to reserve your place at Global Engage's **Research and Technology Series: Immuno-oncology** on the 10th-11th October 2019.

PHONE BOOKING

+44 (0) 1865 849841

maria@globalengage.co.uk

Our conference team will make all the necessary arrangements.

ONLINE BOOKING

Visit the website to book your place

www.global-engage.com/event/research-technology-series

THE CONGRESS PACKAGE INCLUDES:

All Conference Sessions
Lunches and Refreshments
Access to Exhibition Room
Networking Drinks Reception
Conference Workbook
E-Document Pack

HOTEL ACCOMMODATION

Hotel accommodation will be available at a group rate.

FREE NEWSLETTER

For updates on the **Research and Technology Series: Immuno-oncology**, plus free resources and reports, as and when our speakers authorise their release dates, check for updates at:

www.global-engage.com/event/research-technology-series

SPONSORSHIP AND EXHIBITION OPPORTUNITIES AVAILABLE

For more details contact Nick Best or Tony Couch at **sponsorship@globalengage.co.uk**

T: +44 (0) 1865 849841
E: info@globalengage.co.uk
www.global-engage.com

Global Engage Ltd., The Kidlington Centre, Kidlington, Oxford, OX5 2DL, United Kingdom

Follow Us